AMLX
$28.77+5.27%
Amylyx Pharmaceuticals Inc.Stock · HealthcareRussell 2000 · 0.05% of IWMNasdaq Composite · 0.005% of ONEQUS Stock Market · 0.002% of VTIRussell 3000 · 0.002% of IWV
AMLX financial statements
The full income statement, balance sheet, and cash-flow statement for Amylyx Pharmaceuticals Inc. (AMLX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 68.1M2024-09 68.5M2024-12 88.6M2025-03 89.1M2025-06 89.2M2025-09 109.8M2025-12 110.5M2026-03 111.2M2026-06 111.4M+63.7% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 0.00-100.0% | 87.4M-77.1% | 381M+1612.9% | 22.2M+7700.0% | 285K | |
| Cost of revenue | 0.00-100.0% | 5.95M-76.6% | 25.4M+750.0% | 2.99M | — | |
| Research & development | 90.4M-13.1% | 104M-18.8% | 128M+37.2% | 93.5M+112.2% | 44.0M | |
| Selling, general & administrative | 62.9M-45.0% | 114M-39.3% | 188M+48.2% | 127M+226.5% | 38.9M | |
| Restructuring | 0.00-100.0% | 22.9M | — | — | — | |
| Operating income | -153M+51.3% | -315M-911.1% | 38.8M+119.3% | -201M-143.5% | -82.7M | |
| Interest & investment income | 9.30M-32.6% | 13.8M-14.5% | 16.2M+276.5% | 4.29M+11819.4% | 36.0K | |
| Other non-operating income | -700K+42.3% | -1.21M-83.9% | -660K-19.8% | -551K-980.4% | -51.0K | |
| Pre-tax income | -145M+52.1% | -302M-656.5% | 54.3M+127.5% | -198M-124.7% | -87.9M | |
| Income tax | 46.0K+111.7% | -393K-107.8% | 5.03M+549.4% | 774K | — | |
| Net income | -145M+52.0% | -302M-712.4% | 49.3M+124.8% | -198M-125.6% | -87.9M | |
| -$1.53+65.5% | -$4.43-732.9% | $0.70+120.6% | -$3.39+74.6% | -$13.35 | ||
| EPS (basic) | -$1.53+65.5% | -$4.43-706.8% | $0.73+121.5% | -$3.39+74.6% | -$13.35 | |
| Weighted-avg shares (basic) | 94.6M+38.8% | 68.1M+1.4% | 67.2M+14.9% | 58.5M+788.1% | 6.59M | |
| Weighted-avg shares (diluted) | 94.6M+38.8% | 68.1M-2.6% | 70.0M+19.7% | 58.5M+788.1% | 6.59M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 324M+70.9% | 189M-59.2% | 465M+21.6% | 382M+264.1% | 105M | ||
| Cash & equivalents | 227M+192.9% | 77.4M-54.5% | 170M+172.2% | 62.5M+24.6% | 50.2M | |
| Short-term investments | 90.3M-8.9% | 99.1M-50.7% | 201M-29.3% | 284M+519.3% | 45.9M | |
| Accounts receivable | 88.0K-80.3% | 447K-98.9% | 40.0M+161.7% | 15.3M | — | |
| Inventory | — | — | 38.3M+292.3% | 9.77M | — | |
| Prepaid expenses | 6.69M-46.4% | 12.5M-16.4% | 14.9M+47.6% | 10.1M+87.6% | 5.39M | |
| 333M+71.8% | 194M-62.6% | 517M+32.2% | 391M+270.6% | 106M | ||
| Property, plant & equipment | 310K-67.7% | 961K-64.2% | 2.69M+2.9% | 2.61M+450.8% | 474K | |
| Operating lease right-of-use | 5.18M+192.5% | 1.77M-52.5% | 3.73M-32.6% | 5.52M+10.5% | 5.00M | |
| Other non-current assets | 2.50M+10308.3% | 24.0K-96.6% | 701K+50.4% | 466K | — | |
| 22.7M-20.1% | 28.4M-65.4% | 82.0M+76.0% | 46.6M+167.9% | 17.4M | ||
| Accounts payable | 3.52M+19.7% | 2.94M-86.7% | 22.1M+252.6% | 6.26M+43.1% | 4.37M | |
| Accrued liabilities | 17.9M-25.2% | 23.9M-58.5% | 57.7M+50.7% | 38.3M | — | |
| Current lease liability | 1.26M-17.1% | 1.52M-32.7% | 2.26M+10.6% | 2.04M | — | |
| 27.4M-5.1% | 28.9M-65.6% | 84.0M+65.2% | 50.8M+191.7% | 17.4M | ||
| Non-current lease liability | 4.70M+914.7% | 463K-76.6% | 1.98M-53.3% | 4.24M | — | |
| Operating lease liability (total) | 5.96M+200.7% | 1.98M-53.2% | 4.24M-32.5% | 6.28M | — | |
| 305M+85.3% | 165M-62.0% | 433M+27.3% | 341M+325.3% | -151M | ||
| Common stock | 11.0K+57.1% | 7.00K+0.0% | 7.00K+0.0% | 7.00K+600.0% | 1.00K | |
| Additional paid-in capital | 1.06B+36.9% | 772M+4.5% | 738M+6.2% | 695M+14789.8% | 4.67M | |
| Retained earnings | -751M-23.9% | -607M-98.9% | -305M+13.9% | -354M-127.3% | -156M | |
| Accumulated other comprehensive income | 404K+539.1% | -92.0K-146.7% | 197K+329.1% | -86.0K-1055.6% | 9.00K | |
| Total liabilities & equity | 333M+71.8% | 194M-62.6% | 517M+32.2% | 391M+270.6% | 106M | |
| Common shares issued | 110M+60.1% | 68.6M+1.4% | 67.7M+1.8% | 66.5M+847.4% | 7.02M | |
| Common shares outstanding | 110M+60.1% | 68.6M+1.4% | 67.7M+1.8% | 66.5M+847.4% | 7.02M | |
| Shares outstanding (cover) | 111M+24.8% | 88.6M+30.7% | 67.8M+1.6% | 66.7M | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -123M+26.4% | -168M-1506.6% | 11.9M+106.6% | -180M-140.5% | -74.8M | ||
| Depreciation & amortization | 525K-41.9% | 904K-16.9% | 1.09M+123.4% | 487K+836.5% | 52.0K | |
| Share-based compensation | 27.6M-16.3% | 33.0M-11.1% | 37.2M+71.1% | 21.7M+592.4% | 3.14M | |
| Change in receivables | -359K+99.1% | -39.6M-260.0% | 24.7M+61.7% | 15.3M | — | |
| Change in inventory | — | 9.25M-87.3% | 73.1M+648.6% | 9.77M | — | |
| Change in payables | 580K+103.0% | -19.1M-220.3% | 15.9M+756.6% | 1.85M+176.7% | 670K | |
| 14.0M-81.4% | 75.7M-17.8% | 92.1M+138.5% | -239M-415.0% | -46.4M | ||
| Capital expenditure | 138K-12.1% | 157K-87.3% | 1.24M-50.9% | 2.53M+615.6% | 353K | |
| Free cash flow | -123M+26.4% | -168M-1671.5% | 10.7M+105.9% | -182M-142.7% | -75.2M | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchases of investments | 232M-0.1% | 232M-22.9% | 301M-27.7% | 416M+747.8% | 49.1M | |
| 257M+73758.9% | 348K-90.2% | 3.54M-99.2% | 432M+172.4% | 159M | ||
| Long-term debt issued | 256M | 0.00 | 0.00 | 0.00-100.0% | 11.9M | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 1.07M+345.2% | -438K-373.8% | 160K+346.2% | -65.0K-600.0% | 13.0K | |
| Net change in cash | 149M+261.6% | -92.1M-185.5% | 108M+737.0% | 12.9M-65.5% | 37.3M | |
| Income taxes paid | -1.04M-541.7% | 235K-96.3% | 6.39M+23563.0% | 27.0K | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 1.34B+298.7% | 335M-66.3% | 994M-59.4% | 2.45B | — | |
| P/E | — | — | 541.3× | — | — | |
| P/S | — | 3.8×+13.5% | 3.4×-100.0% | 8590.1× | — | |
| P/B | 4.4×+115.2% | 2.0×-14.4% | 2.4×-86.0% | 17.0× | — | |
| Earnings yield | — | — | 0.18% | — | — | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: AMLX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all AMLX filings on SEC EDGAR → Not investment advice.